Application‑based Single Syringe Pump segmentation partitions the market into infusion therapy, drug‑delivery systems, and research & development (R&D) usage. Infusion therapy, which includes intravenous fluid administration, chemotherapy, and anesthesia support, commands the largest share—approximately 45 % of total revenue—driven by the high volume of hospital beds and the regulatory impetus for precise flow control. Drug‑delivery pumps, covering ambulatory insulin, analgesic, and biologic administrations, contribute around 35 % of market value; their growth is propelled by the shift toward home‑care models and the expanding biologics pipeline that requires controlled dosing. R&D applications, encompassing pre‑clinical studies, formulation testing, and academic investigations, represent the remaining 20 % and are characterized by lower unit volumes but higher unit prices due to specialized features such as programmable waveforms and multi‑channel capability. The proportional revenue impact of each application reflects not only the end‑user count but also the average selling price differentials; for instance, R&D pumps, while fewer in number, generate a disproportionate share of profit margins. This granular view of Single Syringe Pump segmentation informs strategic investment decisions across the value chain.